8-K: Qualigen Therapeutics Invests in NanoSynex Funding Round

Qualigen Therapeutics announces its participation as the first investor in NanoSynex's 2025 bridge funding round, aimed at advancing rapid Antimicrobial Susceptibility Testing (AST) technology.

Summary

• Qualigen Therapeutics will participate in the next funding round for NanoSynex.
• NanoSynex is raising up to $500,000 in this bridge round.
• NanoSynex is developing technology for Antimicrobial Susceptibility Testing (AST) that reduces test times and offers more robust diagnostics.
• NanoSynex plans to be approved for the EU market in 2027 and the US market in 2028.
• The global market size for AST is expected to reach $4.7 billion by 2027, with the US market alone reaching $1.6 billion.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the investment in a promising technology and the potential for market growth. However, forward-looking statements are subject to risks and uncertainties.

Positives

• Qualigen's investment supports the development of rapid AST technology.
• NanoSynex's technology has the potential to improve antibiotic use and patient outcomes.
• The AST market presents a significant growth opportunity, projected to reach $4.7 billion globally by 2027.
• NanoSynex has 4 patents protecting the technology.

Risks

• The forward-looking statements are subject to risks and uncertainties, including Qualigen's ability to maintain Nasdaq compliance.
• There are risks related to the company's ability to file its Form 10-Q for the period ended September 30, 2024.
• The potential de-listing of the Company's shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq's continued listing requirement is a risk.

Future Outlook

The company's forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering.

Management Comments

• Kevin Richardson II, CEO of Qualigen, stated that NanoSynex's technology will help the world of Antimicrobial Susceptibility Testing (AST) by reducing test times and offering more robust diagnostics.
• Diane Abensur, CEO of NanoSynex, stated that Qualigen's involvement will allow them to jump start product development of their MVP system for AST, generation 2.0.

Industry Context

This announcement reflects a growing interest in rapid diagnostic technologies within the MedTech industry, particularly in the area of antimicrobial resistance. Faster and more accurate AST methods are crucial for combating antibiotic overuse and improving patient care.

Comparison to Industry Standards

• NanoSynex's technology aims to improve upon existing AST methods by reducing test times, which is a key competitive factor in the diagnostics market.
• The press release highlights that NanoSynex's Minimum Viable Product (MVP) System has numerous competitive advantages to existing tests and is priced competitively with those slower and less robust products.
• Companies like bioMérieux, Roche, and Danaher are major players in the diagnostics market, and NanoSynex is positioning itself to compete by offering faster and more robust AST solutions.

Stakeholder Impact

• Shareholders of Qualigen Therapeutics may be impacted by the investment in NanoSynex.
• The development of rapid AST technology could benefit patients by improving antibiotic use and outcomes.
• NanoSynex's employees and partners may benefit from the funding and product development efforts.

Next Steps

• NanoSynex will use the funding to jump start product development of their MVP system for AST, generation 2.0.
• NanoSynex plans to pursue EU market approval in 2027 and US market approval in 2028.

Key Dates